These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 30615336

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.
    Gilli F, De La Torre AL, Royce DB, Pachner AR.
    Int Immunopharmacol; 2018 Sep; 62():1-6. PubMed ID: 29960044
    [Abstract] [Full Text] [Related]

  • 24. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP.
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [Abstract] [Full Text] [Related]

  • 25. The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies.
    Giantzi V, Karapanayiotides T, Lagoudaki R, Poulatsidou KN, Lourbopoulos A, Daniilidis M, Taskos N, Milonas I, Grigoriadis N.
    Eur Neurol; 2016 Mar; 75(1-2):82-8. PubMed ID: 26867030
    [Abstract] [Full Text] [Related]

  • 26. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C, Gibassier J, Oger J, Le Page E, Edan G.
    Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
    [Abstract] [Full Text] [Related]

  • 27. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic.
    Zarkou S, Carter JL, Wellik KE, Demaerschalk BM, Wingerchuk DM.
    Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436
    [Abstract] [Full Text] [Related]

  • 28. Can we get rid of neutralizing antibodies against interferon-β?
    Buttmann M, Toyka KV.
    Eur J Neurol; 2009 Jan; 16(1):7-9. PubMed ID: 19087143
    [No Abstract] [Full Text] [Related]

  • 29. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
    Shapiro AM, Jack CS, Lapierre Y, Arbour N, Bar-Or A, Antel JP.
    Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
    [Abstract] [Full Text] [Related]

  • 30. Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.
    Wadhwa M, Subramanyam M, Goelz S, Goyal J, Jethwa V, Jones W, Files JG, Kramer D, Bird C, Dilger P, Tovey M, Lallemand C, Thorpe R.
    J Interferon Cytokine Res; 2013 Nov; 33(11):660-71. PubMed ID: 23848523
    [Abstract] [Full Text] [Related]

  • 31. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H, Stelmasiak Z.
    Neurol Neurochir Pol; 2004 Nov; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [Abstract] [Full Text] [Related]

  • 32. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?
    Carlson RJ, Doucette JR, Knox K, Nazarali AJ.
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):249-61. PubMed ID: 25524087
    [Abstract] [Full Text] [Related]

  • 33. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M, Greiner E, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
    [Abstract] [Full Text] [Related]

  • 34. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
    Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M.
    Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
    [Abstract] [Full Text] [Related]

  • 35. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
    Shokrollahi Barough M, Ashtari F, Sadat Akhavi M, Asghari N, Mosayebi G, Mirmohammadkhani M, Kokhaei N, Bahraminia F, Ajami A, Kokhaei P.
    Int Immunopharmacol; 2018 Sep; 62():109-113. PubMed ID: 29990690
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of the impact of neutralizing antibodies on IFNβ response.
    Bertolotto A.
    Clin Chim Acta; 2015 Sep 20; 449():31-6. PubMed ID: 25769291
    [Abstract] [Full Text] [Related]

  • 37. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.
    J Immunol Methods; 2007 Apr 10; 321(1-2):19-31. PubMed ID: 17335844
    [Abstract] [Full Text] [Related]

  • 38. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.
    Mult Scler; 2011 Nov 10; 17(11):1333-40. PubMed ID: 21685230
    [Abstract] [Full Text] [Related]

  • 39. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.
    Bertolotto A.
    Curr Opin Neurol; 2004 Jun 10; 17(3):241-6. PubMed ID: 15167056
    [Abstract] [Full Text] [Related]

  • 40. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta.
    Mayorga C, Luque G, Romero F, Guerrero R, Blanca M, Fernandez O.
    Int Arch Allergy Immunol; 1999 Jun 10; 118(2-4):368-71. PubMed ID: 10224450
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.